Clinical trial · Observational
Surefire Precision Infusion System Registry
NCT02967523CI-TRIAL-00034807terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project involves the collection and analysis of retrospective and prospective data on patients diagnosed with hepatocellular carcinoma (HCC) in which the Surefire Precision Infusion System was used/will used be to deliver transarterial chemoembolization with doxorubicin-eluting beads (DEB-TACE). The purpose is to compare tumor and medical response in a real-world setting as well as identify potential areas for future clinical research.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DEB-TACE with Surefire Precision Infusion System | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Objective tumor response
- timeFrame
- 6 months following initial DEB-TACE procedure.
Secondary outcomes (5)
- measure
- Objective tumor response
- timeFrame
- 1 and 3 months following initial DEB-TACE procedure
- measure
- Dose of doxorubicin-eluting beads used during DEB-TACE procedure(s)
- timeFrame
- 6 months following initial DEB-TACE procedure
- measure
- Tumor characteristics
- timeFrame
- DEB-TACE procedure(s)
- description
- Number of lesions, location of lesions (uni-lobar versus bi-lobar), and distribution (unifocal, multi-focal, diffuse)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who have undergone or will undergo DEB-TACE for HCC delivered by the Surefire® Precision Infusion System * Patients aged 18 years or older * Diagnosis of HCC * Has a discrete hepatic artery(s) feeding the vessel with diameter(s) of the vessels ≥ 1.5 mm Exclusion Criteria: * Contraindications for doxorubicin administration * Vessels providing flow to the tumor that are \< 1.5 mm in diameter(s) * Patients who are unable to provide informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.